{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:09:31Z","timestamp":1759972171443,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K07836"],"award-info":[{"award-number":["JP22K07836"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.braindev.2023.08.005","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T17:17:54Z","timestamp":1693415874000},"page":"62-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up"],"prefix":"10.1016","volume":"46","author":[{"given":"Michinori","family":"Funato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsunari","family":"Kino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reina","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misaki","family":"Yumioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chika","family":"Urui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoya","family":"Uno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Kusukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Minatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2023.08.005_b0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/nbdi.1996.0010","article-title":"The neurobiology of childhood spinal muscular atrophy","volume":"3","author":"Crawford","year":"1996","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.braindev.2023.08.005_b0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.nmd.2008.10.004","article-title":"Ramblings in the history of spinal muscular atrophy","volume":"19","author":"Dubowitz","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2023.08.005_b0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.braindev.2023.08.005_b0020","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"PNAS"},{"key":"10.1016\/j.braindev.2023.08.005_b0025","doi-asserted-by":"crossref","first-page":"8962","DOI":"10.3390\/ijms22168962","article-title":"Drug discovery of spinal muscular atrophy (SMA) from the computational perspective: A comprehensive review","volume":"22","author":"Chong","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.braindev.2023.08.005_b0030","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2023.08.005_b0035","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2023.08.005_b0040","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.braindev.2023.08.005_b0045","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 start trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.braindev.2023.08.005_b0050","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2023.08.005_b0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.braindev.2022.10.006","article-title":"Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2","volume":"45","author":"Iwayama","year":"2023","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2023.08.005_b0060","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the hammersmith functional motor scale for SMA II and III patients","volume":"17","author":"O'Hagen","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2023.08.005_b0065","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418803246","article-title":"Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy","volume":"11","author":"Stolte","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.braindev.2023.08.005_b0070","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2023.08.005_b0075","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s13311-022-01200-3","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a systematic review and meta-analysis","volume":"19","author":"Gavriilaki","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.braindev.2023.08.005_b0080","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.nmd.2022.04.003","article-title":"Longer-term follow-up of nusinersen efficacy and safety in adult patients with spinal muscular atrophy types 2 and 3","volume":"32","author":"Fainmesser","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2023.08.005_b0085","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.nmd.2021.03.012","article-title":"Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen","volume":"31","author":"Coratti","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2023.08.005_b0090","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/acn3.51514","article-title":"Italian ISMAC group. Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy","volume":"9","author":"Pane","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.braindev.2023.08.005_b0095","article-title":"Real-world safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 401 Japanese patients: results from an interim analysis of post-marketing surveillance","author":"Tachibana","year":"2022","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.braindev.2023.08.005_b0100","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1212\/WNL.0000000000009914","article-title":"Nusinersen in adult patients with spinal muscular atrophy: Observations from a single center","volume":"95","author":"Moshe-Lilie","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2023.08.005_b0105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The children's hospital of philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2023.08.005_b0110","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/mus.25705","article-title":"Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam-Part 2: Experience from a nusinersen clinical study","volume":"57","author":"Bishop","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.braindev.2023.08.005_b0115","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: Development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760423001444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760423001444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:51:50Z","timestamp":1759953110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760423001444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0387760423001444"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2023.08.005","relation":{},"ISSN":["0387-7604"],"issn-type":[{"type":"print","value":"0387-7604"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2023.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}